On January 9, as part of PhRMA’s sponsorship of Fierce JPM Week, PhRMA President and CEO Stephen J. Ubl joined Stephanie Butler for a conversation about patient access and affordability. During the conversation, Ubl dove into harmful policies impacting biopharmaceutical innovation, such as the Biden Administration’s recently proposed march-in rights framework, and offered policy solutions that would reduce out-of-pocket costs for patients, like reforms to middlemen known as pharmacy benefit managers (PBMs).

As clinical oncologists gathered in Chicago to meet at the American Society of Clinical Oncology (ASCO)’s Annual Meeting, PhRMA held a media briefing to discuss critical issues facing the future of cancer research and treatment.

Reporters heard from Stephen J. Ubl, President and CEO of PhRMA, alongside industry and patient advocacy leaders on impacts the Inflation Reduction Act (IRA) will have on the research and development (R&D) of cancer treatments. The group also shared the results of a new analysis from the Partnership for Health Analytics and Research (PHAR) on how price setting provisions in the IRA impact R&D for cancer medicines.

On March 30, PhRMA sponsored The Hill’s event, “Pathways to Patient Affordability,” where PhRMA’s President and Chief Executive Officer, Stephen J. Ubl, joined author and journalist, Kathleen Koch, for a conversation about the barriers to achieving patient affordability. In addition to PhRMA’s sponsored segment, the event included a panel of industry experts, and two conversations with members of Congress. 

On January 10, as part of PhRMA’s sponsorship of Fierce Pharma’s J.P. Morgan Health Care Conference event, PhRMA’s COO Lori Reilly joined Fierce Pharma’s Rebecca Willumson for a fireside chat on the initial intent of the 340B program, how the program has shifted away from its original purpose and ways to fix the 340B program so that it works for patients.

On January 9, PhRMA sponsored the “Endpoints at #JPM23” event, where PhRMA’s president and CEO Stephen J. Ubl joined other health care leaders for a panel titled, “What’s really driving the cost of health care in 2023?”

On December 7, PhRMA sponsored the Axios event, “The Post-Midterm Health Care Agenda,” where PhRMA’s Chief Operating Officer Lori Reilly joined Axios Publisher Nicholas Johnston in a View from the Top segment. Reilly discussed how the results of the 2022 midterm elections will shape the 2023 health care agenda, and laid out industry priorities that will protect and support the interests of patients.

On November 15, PhRMA’s President and Chief Executive Officer, Stephen J. Ubl, joined Matthew Herper at the STAT Summit to discuss the newly enacted Inflation Reduction Act and how the law harms biopharmaceutical R&D and doesn’t do enough to address patient affordability and access.

PhRMA sponsored Axios’ virtual event: Whats Next: Health Care Innovation in 2022. Axios health care reporter Caitlin Owens unpacked pandemic-era innovations and the impact on health care in 2022 and beyond.

As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug pricing plan on Capitol Hill, as well as the biopharmaceutical industry’s plans to help build a better health care system that improves patient access and protects innovation.

PhRMA sponsored the Aspen Security Forum and participated in the session Defeating the Virus: The Biden Administration’s Global Vaccination Pledge. This panel discussion was moderated by Kavita Patel, Nonresident Senior Fellow at the Brookings Institution.

PhRMA sponsored The Washington Post Live event: Health Equity: Affordability. Speakers discussed efforts to make health care more affordable in the United States and deliver innovative, quality care to a wider swath of Americans in the aftermath of the COVID-19 pandemic.

The groundbreaking medical research happening today is laying the foundation for a new golden era of medicine. Clinical trials are a vital step in not just ensuring that new innovations are effective, but that they work for all patients.

Axios hosted a virtual event on the COVID-19 vaccine rollout. Axios co-founder Mike Allen and health care reporter Caitlin Owens unpacked the unprecedented COVID-19 vaccine development process as well as the road ahead, featuring NIAID Director Anthony Fauci and Pfizer chairman & CEO Albert Bourla.

Black and Brown Americans have been disproportionately impacted by the COVID-19 pandemic, experiencing a significant share of the devastating health and economic impact of the virus. While vaccines are critical to saving lives and getting the country back to normal, many individuals have questions about getting vaccinated. Black and Brown Americans in particular have important questions and seek to understand how the vaccines were developed and ensuring their safety and efficacy.

PhRMA sponsored the Washington Post Live event: The Lessons of a Pandemic. The event was hosted by Paige Winfield Cunningham, and focused on various lessons learned over the course of the COVID-19 pandemic. Those lessons included vaccinating children, vaccine research and hesitancy, new CDC guidance, and the biopharmaceutical industry’s work to combat the pandemic.

On July 9, 2020, The Hill gathered public health officials, policymakers and leaders from across the healthcare ecosystem to dive into the biggest medical and healthcare trends and innovations, considering both longitudinal trends and their interplay with the recent global health pandemic.